S&P 500   3,768.47
DOW   30,924.14
QQQ   304.10
pixel
S&P 500   3,768.47
DOW   30,924.14
QQQ   304.10
pixel
S&P 500   3,768.47
DOW   30,924.14
QQQ   304.10
pixel
S&P 500   3,768.47
DOW   30,924.14
QQQ   304.10
pixel
Log in
NASDAQ:PRQR

ProQR Therapeutics Stock Forecast, Price & News

$4.48
-0.36 (-7.44 %)
(As of 03/4/2021 12:00 AM ET)
Add
Compare
Today's Range
$4.30
Now: $4.48
$4.86
50-Day Range
$4.25
MA: $4.86
$5.79
52-Week Range
$3.40
Now: $4.48
$8.69
Volume455,724 shs
Average Volume847,551 shs
Market Capitalization$224.64 million
P/E RatioN/A
Dividend YieldN/A
Beta0.73
ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It is primarily developing sepofarsen that is in phase II/III illuminate trial for treating leber's congenital amaurosis 10 disease; QR-421a, which is in phase 1/2 stellar trial for usher syndrome type 2 and non-syndromic retinitis pigmentosa; QR-1123 that is in phase 1/2 aurora trial for the treatment of autosomal dominant retinitis pigmentosa; and QR-504a, which is in first clinical trial for the treatment of fuchs endothelial corneal dystrophy. It has a license agreement with General Hospital Corporation, Radboud University Medical Center, Inserm Transfert SA, and Leiden University Medical Center. ProQR Therapeutics N.V. was founded in 2012 and is headquartered in Leiden, the Netherlands.
ProQR Therapeutics logo

Headlines

Hedge Funds Are Selling ProQR Therapeutics NV (PRQR)
November 30, 2020 |  finance.yahoo.com
ProQR (PRQR) Reports Q3 Loss, Lags Revenue Estimates
November 16, 2020 |  finance.yahoo.com
Ionis With Akcea: Still A Bargain
October 21, 2020 |  seekingalpha.com
ProQR Therapeutics N.V. Aandele (0PQ.SG)
October 9, 2020 |  au.finance.yahoo.com
ProQR Therapeutics Is A Worthy Play
September 14, 2020 |  seekingalpha.com
See More Headlines

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:PRQR
CUSIPN/A
Phone31-88-166-7000
Employees154
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$2.11 per share

Profitability

Net Income$-63,560,000.00

Miscellaneous

Market Cap$224.64 million
Next Earnings Date5/6/2021 (Estimated)
OptionableOptionable

MarketRank

Overall MarketRank

1.37 out of 5 stars

Medical Sector

653rd out of 1,969 stocks

Pharmaceutical Preparations Industry

314th out of 772 stocks

Analyst Opinion: 3.5Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.0 5 -4 -3 -2 -1 -
$4.48
-0.36 (-7.44 %)
(As of 03/4/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive PRQR News and Ratings via Email

Sign-up to receive the latest news and ratings for PRQR and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











ProQR Therapeutics (NASDAQ:PRQR) Frequently Asked Questions

Is ProQR Therapeutics a buy right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for ProQR Therapeutics in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ProQR Therapeutics stock.
View analyst ratings for ProQR Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than ProQR Therapeutics?

Wall Street analysts have given ProQR Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but ProQR Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting ProQR Therapeutics?

ProQR Therapeutics saw a decrease in short interest in January. As of January 29th, there was short interest totaling 870,800 shares, a decrease of 21.5% from the January 14th total of 1,110,000 shares. Based on an average daily trading volume, of 635,900 shares, the days-to-cover ratio is currently 1.4 days.
View ProQR Therapeutics' Short Interest
.

When is ProQR Therapeutics' next earnings date?

ProQR Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, May 6th 2021.
View our earnings forecast for ProQR Therapeutics
.

How were ProQR Therapeutics' earnings last quarter?

ProQR Therapeutics (NASDAQ:PRQR) issued its quarterly earnings data on Thursday, February, 25th. The biopharmaceutical company reported ($0.26) EPS for the quarter, missing the Zacks' consensus estimate of ($0.24) by $0.02.
View ProQR Therapeutics' earnings history
.

How has ProQR Therapeutics' stock been impacted by Coronavirus?

ProQR Therapeutics' stock was trading at $7.00 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, PRQR stock has decreased by 36.0% and is now trading at $4.48.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for PRQR?

3 brokerages have issued 1-year target prices for ProQR Therapeutics' stock. Their forecasts range from $20.00 to $20.00. On average, they anticipate ProQR Therapeutics' stock price to reach $20.00 in the next twelve months. This suggests a possible upside of 346.4% from the stock's current price.
View analysts' price targets for ProQR Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are ProQR Therapeutics' key executives?

ProQR Therapeutics' management team includes the following people:
  • Mr. Daniel Anton de Boer, CEO & Member of Management Board (Age 38)
  • Mr. Gerard Platenburg, Co-Founder & Chief Innovation Officer (Age 57)
  • Ms. Smital Shah M.B.A., Chief Bus. & Financial Officer (Age 45)
  • Dr. Naveed K. Shams, Chief Scientific Officer (Age 64)
  • Ms. Sarah Cue Kiely, VP of Investor Relations & Corp. Communications
  • Ms. Sheila Sponselee, VP of HR
  • Mr. Bart Klein, Sr. VP of Intellectual Property
  • Ms. Bianca Matthee, Head of Manufacturing and Pharmaceutics
  • Mr. Aniz Girach, Chief Medical Officer
  • Ms. Tiffany Burt, Head of Commercial & VP

Who are some of ProQR Therapeutics' key competitors?

What other stocks do shareholders of ProQR Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ProQR Therapeutics investors own include (BIOA) (BIOA), Galapagos (GLPG), SCYNEXIS (SCYX), TG Therapeutics (TGTX), Verastem (VSTM), Corbus Pharmaceuticals (CRBP), Sorrento Therapeutics (SRNE), uniQure (QURE), Viking Therapeutics (VKTX) and Aldeyra Therapeutics (ALDX).

What is ProQR Therapeutics' stock symbol?

ProQR Therapeutics trades on the NASDAQ under the ticker symbol "PRQR."

Who are ProQR Therapeutics' major shareholders?

ProQR Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include Jennison Associates LLC (5.22%), Morgan Stanley (2.02%), JPMorgan Chase & Co. (1.21%), Kerrisdale Advisers LLC (0.90%), Renaissance Technologies LLC (0.67%) and GSA Capital Partners LLP (0.09%).

Which major investors are selling ProQR Therapeutics stock?

PRQR stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., and Jennison Associates LLC.

Which major investors are buying ProQR Therapeutics stock?

PRQR stock was purchased by a variety of institutional investors in the last quarter, including Morgan Stanley, Kerrisdale Advisers LLC, JPMorgan Chase & Co., Renaissance Technologies LLC, GSA Capital Partners LLP, ExodusPoint Capital Management LP, Squarepoint Ops LLC, and Golden Green Inc..

How do I buy shares of ProQR Therapeutics?

Shares of PRQR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is ProQR Therapeutics' stock price today?

One share of PRQR stock can currently be purchased for approximately $4.48.

How much money does ProQR Therapeutics make?

ProQR Therapeutics has a market capitalization of $224.64 million. The biopharmaceutical company earns $-63,560,000.00 in net income (profit) each year or ($1.55) on an earnings per share basis.

How many employees does ProQR Therapeutics have?

ProQR Therapeutics employs 154 workers across the globe.

What is ProQR Therapeutics' official website?

The official website for ProQR Therapeutics is www.proqr.com.

Where are ProQR Therapeutics' headquarters?

ProQR Therapeutics is headquartered at Zernikedreef 9, Leiden P7, 2333 CK.

How can I contact ProQR Therapeutics?

ProQR Therapeutics' mailing address is Zernikedreef 9, Leiden P7, 2333 CK. The biopharmaceutical company can be reached via phone at 31-88-166-7000 or via email at [email protected]


This page was last updated on 3/5/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.